NEPHROBLASTOMA TREATMENT MARKET ANALYSIS

Nephroblastoma Treatment Market, By Type (Favorable histology and Anaplastic histology), By Drug Type (Dactinomycin (Cosmegen), Doxorubicin, Vincristine, Cyclophosphamide, Etoposide, Irinotecan, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On April 4, 2024, Teva Pharmaceutical Industries Ltd, a global pharmaceutical company, announced a strategic licensing agreement with mAbxience, a subsidiary company of Fresenius Kabi AG, a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition, for a biosimilar candidate currently in development for the treatment of multiple oncology indications
On March 28, 2024, researchers at St. Jude Children’s Research Hospital, in Tennessee, U.S., conducted a study to evaluate whether the initial response to neoadjuvant chemotherapy in patients with bilateral Wilms tumor could predict tumor histology. The findings suggest that for tumors that grow during chemotherapy, nephron-sparing surgery should be prioritized over invasive biopsies or increased chemotherapy, especially for patients under 18 months old.
In March 2023, the Children’s Cancer and Leukaemia Group (CCLG), a national charity and expert organization for childhood cancers, announced a new research project focused on improving the diagnosis and monitoring of Wilms tumor, the most prevalent kidney cancer in children. This initiative is crucial as it aims to enhance existing methodologies, ultimately leading to better patient outcomes.